AIRLINK 79.93 Increased By ▲ 0.52 (0.65%)
BOP 5.30 Decreased By ▼ -0.03 (-0.56%)
CNERGY 4.36 Decreased By ▼ -0.02 (-0.46%)
DFML 35.10 Increased By ▲ 1.91 (5.75%)
DGKC 77.60 Increased By ▲ 0.73 (0.95%)
FCCL 20.50 Decreased By ▼ -0.03 (-0.15%)
FFBL 31.53 Increased By ▲ 0.13 (0.41%)
FFL 9.77 Decreased By ▼ -0.08 (-0.81%)
GGL 10.23 Decreased By ▼ -0.02 (-0.2%)
HBL 117.15 Decreased By ▼ -0.78 (-0.66%)
HUBC 133.87 Decreased By ▼ -0.23 (-0.17%)
HUMNL 6.97 Decreased By ▼ -0.03 (-0.43%)
KEL 4.52 Decreased By ▼ -0.15 (-3.21%)
KOSM 4.68 Decreased By ▼ -0.06 (-1.27%)
MLCF 37.51 Increased By ▲ 0.07 (0.19%)
OGDC 136.85 Increased By ▲ 0.15 (0.11%)
PAEL 23.20 Increased By ▲ 0.05 (0.22%)
PIAA 27.03 Increased By ▲ 0.48 (1.81%)
PIBTL 6.92 Decreased By ▼ -0.08 (-1.14%)
PPL 113.49 Decreased By ▼ -0.26 (-0.23%)
PRL 27.43 Decreased By ▼ -0.09 (-0.33%)
PTC 14.80 Increased By ▲ 0.05 (0.34%)
SEARL 57.28 Increased By ▲ 0.08 (0.14%)
SNGP 67.00 Decreased By ▼ -0.50 (-0.74%)
SSGC 11.05 Decreased By ▼ -0.04 (-0.36%)
TELE 9.28 Increased By ▲ 0.05 (0.54%)
TPLP 11.65 Increased By ▲ 0.09 (0.78%)
TRG 72.09 Decreased By ▼ -0.01 (-0.01%)
UNITY 25.60 Increased By ▲ 0.78 (3.14%)
WTL 1.39 Decreased By ▼ -0.01 (-0.71%)
BR100 7,542 Increased By 15.7 (0.21%)
BR30 24,640 Decreased By -9.3 (-0.04%)
KSE100 72,017 Increased By 45.5 (0.06%)
KSE30 23,765 Increased By 16.4 (0.07%)

imagePARIS: Sanofi and Eli Lilly and Co have agreed to pursue regulatory approval for over-the-counter sales of erectile dysfunction treatment Cialis, the French and US drugmakers said in a statement on Wednesday.

Cialis is currently available by prescription only, and was first approved by the European Medicines Agency in 2002 and then by the US Food and Drug Administration in 2003.

It generated $2.16 billion in worldwide sales in 2013 and has recorded total sales of more than $14 billion since launch.

Under the terms of the agreement, Sanofi is buying the exclusive rights to apply for approval of Cialis tablets over the counter in the United States, Europe, Canada and Australia.

Terms of the licensing agreement were not disclosed.

Comments

Comments are closed.